Repository logo
 
Loading...
Thumbnail Image
Publication

Immunotherapy with hymenoptera venom in a child with anaphylaxis

Use this identifier to reference this record.
Name:Description:Size:Format: 
anafilaxia.pdf428.13 KBAdobe PDF Download

Advisor(s)

Abstract(s)

Systemic reactions to hymenoptera venom in childhood are uncommon, comprising less than 1% of cases. The prevalence proves higher in adults, encompassing 0.3−8.9%. Anaphylaxis forms the most severe of all allergic reactions and can be fatal. Specific immunotherapy based on hymenoptera venom is the only treatment that prevents moderate-to-severe systemic reactions. Due to immunotherapy safety and effectiveness, this treatment is indicated during childhood in cases of grade II and III systemic reactions. The authors describe the clinical case of a fourteen-year-old male patient, son of a beekeeper, who was followed in the Allergy and Clinical Immunology Department due to anaphylaxis to hymenoptera venom and was under immunotherapy to Apis mellifera venom since the age of nine, besides complying with measures to evade hymenoptera.

Description

Keywords

anaphylaxis child hymenoptera immunotherapy

Citation

Falcão I, Cunha L, Nascer e Crescer - Birth and Growth Medical Journal 2021;30(2): 114-118. doi:10.25753/BirthGrowthMJ.v30.i2.19718

Research Projects

Organizational Units

Journal Issue

Publisher

Centro Hospitalar Universitário do Porto

Altmetrics